ALK and non-small cell lung carcinoma: Furthermore, while our case report and recent studies suggest promising outcomes with lorlatinib, particularly in managing CNS metastases and overcoming resistance to earlier-generation ALK inhibitors, more robust clinical evidence is needed to optimize treatment strategies and improve patient outcomes in ALK-positive NSCLC.